Hutchison China MediTech (HCM) Prices 4.4M ADS Offering at $25/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Hutchison China MediTech (HCM) Announces Proposed $110M ADS Offering
January 22, 2020 5:42 AM ESTHutchison China MediTech Limited (NASDAQ: HCM) announced today that it intends to offer US$110 million of American Depositary Shares ("ADSs"), each representing five ordinary shares, par value US$0.10 each of Chi-Med, on the Nasdaq Global Select Market ("Offering"). Chi-Med intends to grant the underwriters a 30-day option to purchase up to an aggregate of US$16.5 million of additional ADSs at the public... More
Hutchison China MediTech (HCM) Files to Offer $110M ADSs
January 21, 2020 5:12 PM ESTHutchison China MediTech (NASDAQ: HCM) disclosed:
We are offering US$110,000,000 of American depositary shares, or ADSs, representing of our ordinary shares, par value US$0.10 per share. Each ADS represents five ordinary shares.
Our ADSs are listed on the Nasdaq Global Select... More
Hutchison China MediTech (HCM) Reports Surufatinib Phase III SANET-p Study Has Already Achieved Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China; Will Stop Early
January 21, 2020 5:57 AM ESTHutchison China MediTech Limited (NASDAQ: HCM) today announces that the independent Data Monitoring Committee (IDMC) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors pancreatic (SANET-p) has completed a pre-planned interim analysis. The IDMC recommended that the study stops early as the pre-defined primary endpoint of progression free survival (PFS) had already been met.
Following the early success of this study, Chi-Med now plans to arrange a pre-New Drug Application (NDA) meeting with the China National Medical... More
